Survodutide - Role in MASH

Survodutide is emerging as a promising treatment for metabolic dysfunction–associated steatohepatitis (MASH), a progressive form of metabolic dysfunction–associated steatotic liver disease (MASLD). Survodutide functions as a dual agonist of glucagon-like peptide-1 (GLP-1) and glucagon receptors, targeting both metabolic and hepatic pathways central to MASH pathology. By activating GLP-1 receptors, Survodutide reduces appetite and improves insulin resistance, while glucagon receptor activation decreases liver fat production, potentially reversing key aspects of MASH.

In a 48-week multicenter trial involving 293 patients with biopsy-confirmed MASH, Survodutide demonstrated robust efficacy. Between 43–62% of patients treated with Survodutide achieved histologic resolution of MASH, compared to 14% in the placebo group. Furthermore, over 57% of participants experienced at least a 30% reduction in liver fat, highlighting its strong metabolic and hepatic benefits. These outcomes underscore the drug’s potential in addressing both liver inflammation and fat accumulation, critical drivers of MASH progression.

Despite its efficacy, Survodutide’s safety profile revealed notable gastrointestinal adverse effects, including nausea, vomiting, and diarrhea. These side effects led to treatment discontinuation in approximately 20% of patients, significantly higher than the 3% discontinuation rate in the placebo group.

Survodutide’s promising results align with findings from tirzepatide, another dual receptor agonist targeting GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). Both drugs significantly outperform prior MASH treatments, offering hope for future combination or sequential therapies. However, larger, longer-term studies are needed to confirm Survodutide’s sustained benefits and long-term safety, particularly in diverse patient populations.